 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease |
| Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim, |
|
Intest Res. 2023;21(1):43-60. Published online October 18, 2022 DOI: https://doi.org/10.5217/ir.2022.00029 |
|
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease Intestinal Research. 2023;21(1):43-60  Providing the Best Care for Patients With Crohn’s Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease Gastroenterology. 2021;160(7):2557-2562 First-Line and Second-Line Biologics in the Management of Moderate-Severe Crohn’s Disease: A Grade-Based Approach Gastroenterology. 2017;152(5):S592 A Cost-utility analysis of Biologics for moderate-to-severe Crohn’s disease: evidence synthesis using a Bayesian Network meta-analysis Value in Health. 2015;18(3):A224-A225 Biologics in oral medicine: oral Crohn’s disease and orofacial granulomatosis Oral Diseases. 2012;18(7):633-638 Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohn’s Disease: A 1-Year Treatment Sequence Analysis Value in Health. 2016;19(7):A576 Su1928 – Tofacitinib Improves Clinical Disease Activity in a Real-World Population of Patients with Moderate-Severe Ulcerative Colitis and Crohn’s Disease Gastroenterology. 2019;156(6):S-664 Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data British Journal of Dermatology. 2012;167:3-11 Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis Intestinal Research. 2023;21(1):61-87 Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial Canadian Journal of Gastroenterology. 2011;25(8):419-425 |
